Article

“Feel good” factors identified for patients with fibromyalgia

In patients with fibromyalgia syndrome (FMS), the global impression of improvement is correlated with changes in clinical rating scale items or subscales assessing multiple symptom domains.

In patients with fibromyalgia syndrome (FMS), the global impression of improvement is correlated with changes in clinical rating scale items or subscales assessing multiple symptom domains. In addition to pain reduction, factors that may contribute to perceptions of improvement among patients with FMS include improvement in fatigue, physical functioning, mood, and impact on daily living.

Hudson and associates examined pooled data from 4 randomized, double-blind, placebo-controlled studies of duloxetine in patients with FMS. The studies used several rating scales, including the Patient Global Impression of Improvement (PGI-I), to evaluate clinical domains identified as important by the Outcomes Measures for Rheumatoid Arthritis Clinical Trials (OMERACT). The investigators based their analysis on 7 patient-rated scales and 1 clinician-rated scale and examined how the scores from each domain correlated with the PGI-I.

Correlating most closely were changes in scores for pain, physical functioning, fatigue, and impact on daily living-domains also identified by OMERACT as most significant to quality of life. None of the variables in the emotional well-being domain (eg, motivation, depression) were highly correlated with the PGI-I.

The authors noted that the former domains may be important for outcome assessments in clinical trials and in the treatment of patients with FMS.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.